According to MarketsandMarkets(TM), the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 ...

Researchers at the University of Geneva have built a molecular system that can tell the difference between a cancer cell and ...

Researchers at the Université de Genève have built a DNA-based drug delivery system that reads pairs of protein markers on a ...

The 2026 PSMA & Beyond conference featured a targeting the cell surface session and presentation by Dr. Tanya Dorff discussing antibody drug conjugates and BiTEs and their role in prostate cancer. Dr.

DUBLIN--(BUSINESS WIRE)--The "Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape & Market Opportunity Insight 2025" report has been added to ...

With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...

You may have heard of the consulting firm Gartner’s technology hype cycle—the technology trigger, the peak of inflated expectations, the trough of disillusionment, the slope of enlightenment, and the ...

The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...

According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%.